Abstract:Neural stem/progenitor cell (NSPC) based therapy represents an attractive treatment for Alzheimer's disease (AD), the most common neurodegenerative disorder with no effective treatment to date. This can be achieved by stimulating endogenous NSPCs and/or administrating exogenously produced NSPCs. Successful repair requires the migration of NSPCs to the loci where neuronal loss occurs, differentiation and integration into neural networks. However, the progressive loss of neurons in the brain of AD patients suggests that the repair by endogenous NSPCs in the setting of AD may be defective. The production and deposition of amyloid-β1-42 (Aβ1-42) peptides is thought to be a central event in the pathogenesis of AD. Here we report that Aβ1-42 peptides inhibit the migration of in vitro cultured NSPCs by disturbing the ERK-MAPK signal pathway. We found that the migratory capacity of NSPCs was compromised upon treatment with oligomeric Aβ1-42; the inhibitory effect occurred in a dose-dependent manner. Our previous studies have shown that Aβ1-42 triggers the expression of GRK2 by unknown mechanism. Herein we found that the Aβ1-42 evoked upregulation of GRK2 expression was attenuated upon treatment with the ERK inhibitor SCH772984 at 2.5 μM, but not with inhibitors for p38 or JNK. We detected a dose-dependent increase in levels of phosphorylated ERK1/2 after incubation of cells with oligomeric Aβ1-42 peptides for 3 days. We observed that an increase in the phosphorylation of p38 and JNK coincided with reduced phosphorylation of ERK1/2 upon treatment with Aβ1-42 for 6 and/or 9 days. We hypothesize that the divergence of the activation of the MAPK family of pathways may contribute to the inhibition of NSPCs migration after the long-term incubation with Aβ1-42. Pretreatment with 1  μM MEK inhibitor U0126 reversed the effects of Aβ1-42 on GRK2 expression of and NSPC migration. Together, our results suggest that Aβ1-42 oligomers compromise the migratory capacity of NSPCs through the MEK-ERK pathway.

Autophagy-ERK1/2-Involved Disinhibition of Hippocampal Neurons Contributes to the Pre-Synaptic Toxicity Induced by Aβ42 Exposure.

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

Protective effect of EGb761 against Aβ1-42 -induced SHSY5Y cells injury and blood-brain barrier disruption via regulating Akt/Nrf2 signaling pathway

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

The preliminary experiment study on the ERK signal transduction pathway involved in PC12 nervous synaptic change induced by Aβ_(1-40)

Resveratrol Attenuates Aβ-Induced Early Hippocampal Neuron Excitability Impairment via Recovery of Function of Potassium Channels

ERβ promotes Aβ degradation via the modulation of autophagy

RETRACTED: the Synergistic Effect Between Β-Amyloid1–42 and Α-Synuclein on the Synapses Dysfunction in Hippocampal Neurons

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

P1‐210: DAPK1 IS REQUIRED FOR THE EARLY NEURONAL DAMAGE AND COGNITIVE IMPAIRMENT INDUCED BY Aβ OLIGOMERS

Acute Impairment of Mitochondrial Trafficking by Beta-Amyloid Peptides in Hippocampal Neurons

Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

EGb761 Protects Against Aβ1-42 Oligomer-Induced Cell Damage Via Endoplasmic Reticulum Stress Activation Andhsp70 Protein Expression Increase in SH-SY5Y Cells

Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential

Activation of β 2 -adrenergic receptors prevents AD-type synaptotoxicity via epigenetic mechanisms

Amyloid-β1-42 Dynamically Regulates the Migration of Neural Stem/progenitor Cells Via MAPK-ERK Pathway.

Soluble Β-Amyloid Impaired the GABA Inhibition by Mediating KCC2 in Early APP/PS1 Mice.

Activation of β2-adrenergic receptors prevents AD-type synaptotoxicity via epigenetic mechanisms

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

PI3K/AKT/mTOR/p70S6K Pathway Is Involved in Aβ25-35-Induced Autophagy.